Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Apple Tree Partners United States

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

Website:
http://www.appletreepartners.com
Year Founded
1999
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Sam Hall
Principal 
Aaron Kantoff
Vice President 

Artiman Ventures

Artiman is a venture capital company founded in 2 and based in Palo Alto California. The firm is currently making investments out of its fourth $2 million fund. The firm makes seed and venture investments into firms ranging from a few hundred thousand to $5 million depending on the stage and financial requirements of the company. The firm has a preference for companies based in Silicon Valley but will consider opportunities globally and looks to make around 5 investments per year.
Website:
www.artiman.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Akhil Saklecha
Managing Director 

Asset Management Ventures

Asset Management Ventures is a private investment firm funded by a single LP and is based in California USA. The firm invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $25K to $1M (usually in equity or convertible notes). For early-stage companies the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company?s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.
Website:
www.assetman.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Capital Structure Preference
Investment Stage Preference
Richard Simoni
Managing Partner 

ATEM Capital

ATEM Capital manages evergreen Life Sciences investment fund - Health Square Fund (HSF). HSF acts as a consolidator of capital flows from the Emerging Markets and invests into the biotech innovation hubs of the US/Western Europe. HSF's international team combines big-picture business perspective with decades of investment scientific legal portfolio risk management and operational experience. The fund is audited by a Big-4 firm. Our Advisory Board comprises high-caliber entrepreneurs VC veterans and seasoned Wall Street professionals.
Website:
www.atemcap.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Alexey Afanasiev
Executive Partner 
Anton Gopka
CEO General Partner 
Elena Ikhsanova
COO General Partner 

Baird Venture Partners

Baird Venture Partners is the venture and expansion capital arm of Robert W. Baird & Co. The Baird Venture Partners team is based in Chicago Illinois and has around $27 million in total assets under management. In 214 Baird closed a fourth venture capital fund at $185 million. The firm is currently seeking opportunities in the life science sector and while Baird has no strict timeline to make investments the group would invest in a new firm within the next 6-9 months if a compelling opportunity was identified. The firm?s equity investments range from $3-1 million but are typically in the $8-1 million range.The firm will only consider investment into US based firms.
Website:
www.rwbaird.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Momei Qu
Senior Associate 

Band of Angels

The Band of Angels is a funding organization that was founded in 1994 and it is based in Silicon Valley California. The organization typically provides capital to companies through three programs: The Band of Angels Acorn Fund and The Band of Angels Venture Fund. The group focuses on seed and Series A stage high-tech companies across several industries including life science space. The Band of Angels generally makes investments ranging from $3K to $75k but it often leads a syndication of $2-3million. Acorn Fund which is The Band?s third side fund and was founded in 29 generally makes investments ranging from $1k to $75k. The Band of Angels Venture Fund is a $5 million venture fund which raised in 1999 by The Band of Angels. Initial investment sizes of the fund are typically $3 and can go up to $2.5 million. The Band generally makes around 1 -2 investments per year. The group focuses on companies based in Silicon Valley but it will consider selective opportunities in Los Angles and San Diego areas. The group's portfolio includes biotechnology and medical device companies working with oncology and muscle recovery.
Website:
www.tosk.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Brian Frenzel
Member 
Michael Bates
Member, Board of Directors 

Baxter Ventures

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Priyanka Rohatgi
Director 

Becton Dickinson (BD)

BD (Becton Dickinson and Company) based in Franklin Lakes NJ is a leading medical technology company that partners with customers and stakeholders to address many of the world?s most pressing and evolving health needs. Their innovative solutions are focused on improving drug delivery enhancing the diagnosis of infectious diseases and cancers supporting the management of diabetes and advancing cellular research. The firm has nearly 3 associates in 5 countries who strive to fulfill our purpose of ?Helping all people live healthy lives? by advancing the quality accessibility safety and affordability of healthcare around the world. For more information please visit www.bd.com. BD partners with companies from their formation through to commercialization including expansion of operations and channel access. BD considers a variety of engagement models including research collaborations licenses investments and acquisition when partnering with companies aligned with BD?s core businesses and new areas of strategic interest seeking opportunities from around the globe.
Website:
www.bd.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Albert Lauritano
Director Strategic Technology Partnerships 

BioScience Managers Australia

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Website:
http://www.biosciencemanagers.com/
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jeremy Curnock Cook
Managing Director 
Amanda Gillon
Investment Analyst 
Matt McNamara
CIO 

Biosight, LLC and MIT United States

Biosight, LLC  is a start-up biomedical device company developing a low-cost technology that will enable health care providers (HCPs) to discriminate amongst different types of tissues so that they will no longer need to use the blind and semi-blind approach to procedural instrument placement. The key intellectual capital of Biosight, LLC, (Biosight) is medical procedure needle tip tissue identification using multimodal spectroscopy (MMS) technologies first developed in the Laser Biomedical Research Center (LBRC) at the Massachusetts Institute of Technology. Several founding members of Biosight are the pioneers in this field and have established collaborations with clinicians at the Massachusetts General Hospital to identify clinical areas for this technology. Currently, Biosight, LLC is working with several investors in Massachusetts to further develop the device for numerous clinical applications

Year Founded
2014
Main Sector
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Alliance & Collaborations
Massachusetts Institute of Technology and Massachusetts General Hospital
Current Financing Needs
$10M
IP Status
Application Filed
Recent Milestones
Finalist in MIT 100K Pitch 2014
Management Team Highlights
Harvard and MIT Collaborators
Cheryl Campbell
Cheryl Campbell
LinkedIn logo MIT MBA Student and Intellectual Property Attorney 
BIO

A cancer scientist, corporate/IP lawyer and MBA candidate at the MIT Sloan School of Management who is dedicated to commercializing innovative biopharmaceutical products and medical devices that benefit patients. I have acquired diverse experience in the health care and life sciences industries spanning discovery, commercialization and regulatory development. My goal is to create and execute business and legal strategies that successfully drive products to market and create overall value for patient care. Capabilities include research design, assay development, clinical trial management, market/financial analysis, data modeling, operational design and management, system dynamics, drafting regulations, stakeholder engagement, intellectual property, licensing and contract drafting/negotiations.